CN103995116A - 用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 - Google Patents
用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 Download PDFInfo
- Publication number
- CN103995116A CN103995116A CN201410232547.4A CN201410232547A CN103995116A CN 103995116 A CN103995116 A CN 103995116A CN 201410232547 A CN201410232547 A CN 201410232547A CN 103995116 A CN103995116 A CN 103995116A
- Authority
- CN
- China
- Prior art keywords
- cephalosporins
- solution
- test strips
- antigen
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124587 cephalosporin Drugs 0.000 title claims abstract description 45
- 229930186147 Cephalosporin Natural products 0.000 title claims abstract description 41
- 150000001780 cephalosporins Chemical class 0.000 title claims abstract description 41
- 238000012360 testing method Methods 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000013566 allergen Substances 0.000 title abstract description 12
- 108060003951 Immunoglobulin Proteins 0.000 title abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract description 3
- 230000003115 biocidal effect Effects 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 27
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 7
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 229920002301 cellulose acetate Polymers 0.000 claims abstract description 4
- 239000010931 gold Substances 0.000 claims description 23
- 229910052737 gold Inorganic materials 0.000 claims description 23
- 239000000084 colloidal system Substances 0.000 claims description 22
- 230000000890 antigenic effect Effects 0.000 claims description 21
- 239000003381 stabilizer Substances 0.000 claims description 17
- 229960001991 ceftizoxime Drugs 0.000 claims description 14
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 229920000151 polyglycol Polymers 0.000 claims description 10
- 239000010695 polyglycol Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 7
- 239000012506 Sephacryl® Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229960002682 cefoxitin Drugs 0.000 claims description 4
- 229960002588 cefradine Drugs 0.000 claims description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960004841 cefadroxil Drugs 0.000 claims description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
- 229960003866 cefaloridine Drugs 0.000 claims description 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 2
- 229960003012 cefamandole Drugs 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960003585 cefmetazole Drugs 0.000 claims description 2
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 claims description 2
- 229960002025 cefminox Drugs 0.000 claims description 2
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 2
- 229960005495 cefotetan Drugs 0.000 claims description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 2
- 229960001242 cefotiam Drugs 0.000 claims description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 claims description 2
- 229960000466 cefpirome Drugs 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 claims description 2
- 229950000807 cefuzonam Drugs 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims 2
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000002372 labelling Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 39
- 238000003745 diagnosis Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000219095 Vitis Species 0.000 description 5
- 235000009754 Vitis X bourquina Nutrition 0.000 description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 description 5
- 235000014787 Vitis vinifera Nutrition 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003547 immunosorbent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 241000532370 Atla Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- -1 salt ion Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供一种用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条,所述试纸条包被有胶体金标记的头孢菌素类抗生素抗原。本发明利用胶体金标记技术,首次用胶体金标记特异性头孢菌素类抗生素过敏原,然后将标记后的过敏原均匀喷线于醋酸纤维素膜或硝酸纤维素膜上,制备成试纸条产品进行过敏原检测,操作简便,结果准确,成本低廉,可实现多项自由检测。
Description
技术领域
本发明涉及胶体金标记技术领域,具体地说,涉及一种用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法。
背景技术
过敏性疾病是当代社会中最常见的一种疾病,它是由广泛存在的过敏原引起的,我国约5~10%、美国和欧洲约5~25%的人群遭受过过敏性侵扰,其中幼儿和青少年尤为明显,危害较严重。过敏反应(allergy)是免疫机体再次接触相同变应原时,发生反应过度剧烈而引起的生理功能紊乱和组织损伤的病理性免疫反应。涉及临床各科,如内科包括支气管哮喘、过敏性休克、血清病、结缔组织病、肾小球肾炎、偏头痛等,外科包括移植排异反应、耳鼻喉科有过敏性鼻炎、渗出性中耳炎、美尼尔病等,妇产科包括新生儿溶血症,眼科包括过敏性结膜炎、交感性眼炎,口腔科包括复发性口疮,皮肤科约半数以上的疾病为过敏反应病,另外还有输血反应、药物过敏、过敏性休克等。
2011年4月国家统计局颁布的的调查统计数据显示,全国城市人口约5.7亿,其中有1.5亿城市过敏原发病人口,常年处于过敏原状态的人群达5122万人。据此估算,中国人口城市变态反应疾病发病率为27%,加上非城市人口,实际中国变态反应疾病发病人数约为3.6亿。然而,近十年来,我国过敏原患者的诊治率不到1%,近99%的过敏原患者得不到及时的诊断和治疗。
据不完全统计,全国15000家县级以上医院中引进UniCAP的不足150家,引进率仅占1%。这一比例与其他生化检测设备(约40~50%)的引进率相比,足以说明过敏原的体外诊断领域存在着巨大发展空 间。同时,体外过敏原检测设备和试剂主要依赖进口,这些原料均采自欧美的进口过敏原试剂,与我国患者的地域差和人种差也有待验证。基于上述情况,开发一种符合本土化要求的过敏原检测系统,包括我国自主创新的过敏原检测仪和试剂在内的研发势在必行。
过敏原检测的方法主要分为体内诊断和体外诊断。体内诊断包括皮肤诊断(定性检查)和激发诊断。常见的皮肤诊断包括皮内实验、点刺实验、划痕实验、斑贴实验等。激发诊断包括结膜实验、鼻实验、支气管实验、食物实验、药物激发实验、物理性激发实验等。由于体内诊断的影响因素复杂,准确性低,结果只能进行定性,且检查本身给患者带来痛苦,对严重过敏患者甚至存在生命危险等诸多因素,限制了体内诊断的进一步发展。
体外诊断的原理是基于IgE抗体诊断,在诊断技术上包括免疫印记法、放射变应原吸附诊断(RAST)、荧光酶标法(FEIA)、酶联免疫法(ELISA)等。
目前,国内常用的临床检测过敏原的方法是以皮肤针刺试验(SPT)为主的体内试验方法,即用稀释过敏原液直接点刺皮肤,观察检测点是否出现风团或潮红反应,进行阴性或阳性判定。SPT虽然有简便,成本低,患者可见结果等优点。但是其结果受诸多因素影响,准确性低,检查本身给患者尤其是小儿患者带来痛苦,对严重过敏患者甚至有生命危险。国内体外诊断领域处于落后状态,基本集中在手工操作和半定量半自动分析状态。存在操作烦琐、灵敏度和精密度差,测试时间长的缺点。
与体内试验相比,只需少量血清即可筛选和确定百种过敏原,具有效能参数可靠,不受药物影响,无全身反应危险等显著优点。应用比较突出的是PHARDIA UNICAP系统和SIEMENS诊断系统。PHARDIA UNICAP系统自70年代问世以来,一直被作为过敏原诊断的金标准。80年代进入中国,一直处于垄断地位。而SIEMENS诊断 系统是过敏原自动化新技术的代表,是近几年新兴的过敏原诊断系统,尚未进入中国市场。
在发达国家,临床上通行的全自动过敏原检测是基于酶联免疫法。常用两种方法:酶联免疫荧光测定法和生物素-亲和素系统-酶联免疫法。
酶联免疫荧光测定法的经典系统是Pharmacia(法玛西亚)公司的Immuno CAP检测系统,它采用纤维素固相载体,该固相载体经溴化氧活化后与过敏原共价结合。过敏原预先结合在固相载体上,加入血样后37℃孵育,如患者血清中有针对该过敏原的特异性IgE,即形成抗此过敏原抗体复合物。洗脱后加入酶标记的酶标二抗,形成固相载体-过敏原-特异性IgE-酶标二抗的结合物。再次洗脱后加入底物,产生酶催化荧光产物。测定荧光值。根据荧光吸光度的大小换算成特异性IgE含量。
生物素-亲和素系统-酶联免疫法采用Fooke公司的ALLERG-O-LIQ测定系统,酶标板由抗人IgE抗体包被,可用来检测总IgE和特异性IgE。加入血样后孵育和洗涤,酶标板结合所有IgE,洗涤可避免其他免疫球蛋干扰(如特异性抗原),再加入生物素标记的过敏原,然后加入结合了酶的链霉亲和素结合物和显色底物,通过酶与底物反应后吸光度的变化来检测针对特异性过敏原的IgE含量。
发明内容
本发明的目的是提供一种用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条。
本发明的另一目的是提供所述试纸条的制备方法。
为了实现本发明目的,本发明的一种用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条,所述试纸条包被有胶体金标记的头孢菌素类抗生素抗原。
具体地,本发明所述试纸条为包被有胶体金标记的头孢菌素类抗 生素抗原的硝酸纤维素膜或醋酸纤维素膜。
其中,所述试纸条的pH值为8.5-10,胶体金颗粒与头孢菌素类抗生素抗原之间的摩尔比为5-10:1。所述头孢菌素类抗生素包括但不限于头孢噻吩、头孢噻啶、头孢唑啉、头孢拉定、头孢氨苄、头孢拉定、头孢羟氨苄、头孢克罗、头孢孟多、头孢替安、头孢呋新、头孢美唑、头孢西丁、头孢替坦、头孢噻肟、头孢唑肟、头孢曲松、头孢他啶、头孢米诺、头孢哌酮、头孢匹罗、头孢唑南等。
优选地,所述头孢菌素类抗生素抗原为注射用头孢唑肟。
本发明还提供所述试纸条的制备方法,包括以下步骤:
1)头孢菌素类抗原溶液的制备:将待标记的头孢菌素类抗原溶解在0.9%pH7.0的NaCl溶液中,使其终浓度为50-500μg/ml,即得头孢菌素类抗原溶液;
2)胶体金溶液的制备:用0.1M K2CO3溶液和0.1M HCl调0.01%HAuCl4胶体金溶液的pH值至8.5-10,使胶体金的粒径达到40-60nm,浓度达到0.5-2%,即得胶体金溶液;
3)胶体金与头孢菌素类抗原的结合:用0.1M K2CO3溶液调步骤1)的抗原溶液的pH值至8.5-10,边搅拌边向其中加入步骤2)的胶体金溶液,抗原溶液与胶体金溶液的体积比为1-10:100,同时加入稳定剂以防止头孢菌素类抗原与胶体金颗粒聚合沉淀,即得胶体金-头孢菌素类抗原结合物;所述稳定剂为BSA(牛血清白蛋白)和分子量20KD的聚乙二醇,二者终浓度分别为1%和0.1%;
4)胶体金标记的头孢菌素类抗原的纯化:将步骤3)中制备的胶体金-头孢菌素类抗原结合物经1500r/min离心20min;收集沉淀溶于稳定剂中,使其浓度达到5-30%;然后加至Sephacryl S-400层析柱上进行纯化,将纯化的胶体金标记的头孢菌素类抗原溶液过滤除菌,4℃保存;所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液;
5)试纸条的包被:将步骤4)中制备的胶体金标记的头孢菌素类 抗原溶液喷线于试纸条上,干燥后即得用于特异性头孢菌素类过敏原IgE筛查的试纸条成品。
前述的制备方法,步骤4)中加样量为Sephacryl S-400层析柱体积的1/10,以稳定剂作为洗脱液,流速为5-10ml/h;所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液。
使用时,将本发明的试纸条浸入人血清中,使血清中IgE抗体与特异性过敏原结合,产生紫色条带。根据条带颜色的深浅对照比色卡进行分级,
本发明利用胶体金标记技术,首次用胶体金标记特异性头孢菌素类抗生素过敏原抗原,然后将标记后的过敏原均匀喷线于醋酸纤维素膜或硝酸纤维素膜上,制备成试纸条产品进行过敏原检测,操作简便,结果准确,成本低廉,可实现多项自由检测。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段,所用原料均为市售商品。
实施例用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法
用于特异性头孢唑肟过敏原IgE筛查的试纸条的制备包括待标记抗原溶液的制备、待标胶体金溶液的制备、胶体金标记头孢唑肟抗原、胶体金头孢唑肟抗原的纯化、胶体金蛋白颗粒的粒径鉴定以及试纸条的包被。具体步骤如下:
1、待标记抗原溶液的制备
所述头孢菌素类抗生素抗原为注射用头孢唑肟。
将头孢唑肟抗原溶解在0.9%pH7.0NaCl溶液中,使其终浓度为50-500μg/ml,4℃透析过夜,以除去多余的盐离子,即得头孢唑肟抗原溶液。
2、待标胶体金溶液的制备
用0.1M K2CO3溶液或0.1M HCl调胶体金溶液的pH值至9.0,使胶体金的粒径达到50nm,浓度达到1%。
3、胶体金标记头孢唑肟抗原:将胶体金和抗原溶液分别用0.1MK2CO3溶液调pH至9.0,电磁搅拌抗原溶液,加入胶体金溶液,抗原溶液与胶体金溶液的体积比为1-10:100,继续搅拌10min,加入稳定剂BSA和分子量20KD的聚乙二醇,得到1%BSA和0.1%分子量20KD的聚乙二醇溶液。此过程需要调整抗原的用量,以胶体金标记抗原完成后的溶液呈葡萄酒红色为最佳。
4、胶体金标记的头孢唑肟抗原的纯化:将步骤3中制备的胶体金-头孢唑肟抗原结合物经1500r/min离心20min;收集沉淀溶于稳定剂(所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液)中,使其浓度达到5-30%;然后加至Sephacryl S-400层析柱上进行纯化,将纯化的胶体金标记的头孢唑肟抗原溶液过滤除菌,4℃保存。
纯化过程中,加样量为Sephacryl S-400层析柱体积的1/10,以稳定剂(所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液)作为洗脱液,流速为5-10ml/h。
5、胶体金蛋白颗粒的粒径鉴定
胶体金颗粒平均直径的测量:在透射电镜下观察胶体金颗粒,计算100个金颗粒的平均直径应在40~60nm范围内。
6、试纸条的包被
将阴性对照溶液(含40-70%牛血清白蛋白的PBS溶液),步骤4纯化的抗原溶液进行均匀喷线。
在免疫层析试纸硝酸纤维素膜表面进行阴性对照和抗原溶液的喷线。用气动喷头进行定量操作。用三维平台往复来回间隔喷线。最后将喷好的硝酸纤维素膜干燥并裁切成条。
7、结果判断
根据条带颜色的深浅对照比色卡进行分级,分级方法见表1:
表1分级标准
血清中IgE浓度 | 分级 | 特异性IgE含量 |
<0.35IU/mL | 0 | 无 |
0.35-0.75IU/mL | 1 | 低 |
0.75-3.5IU/mL | 2 | 增加 |
3.5-17.5IU/mL | 3 | 显著增加 |
17.5-50IU/mL | 4 | 显著增加 |
50-100IU/mL | 5 | 较高 |
>100IU/mL | 6 | 极高 |
目测比色中,比色卡上的条带为在免疫层析试纸硝酸纤维素膜表面直接进行葡萄皮红喷线。根据喷线葡萄皮红的浓度不同形成梯度(表2):
表2不同IgE浓度对应于比色卡上葡萄皮红的浓度
血清中IgE浓度 | 葡萄皮红浓度 |
<0.35IU/mL | 无 |
0.35-0.75IU/mL | 0.25g/L |
0.75-3.5IU/mL | 0.5g/L |
3.5-17.5IU/mL | 2g/L |
17.5-50IU/mL | 5g/L |
50-100IU/mL | 9g/L |
>100IU/mL | 12g/L |
本发明提供的用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条适于工业化大规模生产,降低了生产成本,大大降低了过敏原单项检测的价格。另外,对具有中国本土特点的过敏原原料,实现本土化,更适于中国人群过敏原的诊断,提高了诊断的准确性。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详 尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (7)
1.一种用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条,其特征在于,所述试纸条包被有胶体金标记的头孢菌素类抗生素抗原。
2.根据权利要求1所述的试纸条,其特征在于,所述试纸条为包被有胶体金标记的头孢菌素类抗生素抗原的硝酸纤维素膜或醋酸纤维素膜。
3.根据权利要求1所述的试纸条,其特征在于,所述试纸条的pH值为8.5-10,胶体金颗粒与头孢菌素类抗生素抗原之间的摩尔比为5-10:1。
4.根据权利要求1-3任一项所述的试纸条,其特征在于,所述头孢菌素类抗生素包括但不限于头孢噻吩、头孢噻啶、头孢唑啉、头孢拉定、头孢氨苄、头孢拉定、头孢羟氨苄、头孢克罗、头孢孟多、头孢替安、头孢呋新、头孢美唑、头孢西丁、头孢替坦、头孢噻肟、头孢唑肟、头孢曲松、头孢他啶、头孢米诺、头孢哌酮、头孢匹罗、头孢唑南。
5.根据权利要求4所述的试纸条,其特征在于,所述头孢菌素类抗生素抗原为注射用头孢唑肟。
6.权利要求1-5任一项所述试纸条的制备方法,其特征在于,包括以下步骤:
1)头孢菌素类抗原溶液的制备:将待标记的头孢菌素类抗原溶解在0.9%pH7.0的NaCl溶液中,使其终浓度为50-500μg/ml,即得头孢菌素类抗原溶液;
2)胶体金溶液的制备:用0.1M K2CO3溶液和0.1M HCl调0.01%HAuCl4胶体金溶液的pH值至8.5-10,使胶体金的粒径达到40-60nm,浓度达到0.5-2%,即得胶体金溶液;
3)胶体金与头孢菌素类抗原的结合:用0.1M K2CO3溶液调步骤1)的抗原溶液的pH值至8.5-10,边搅拌边向其中加入步骤2)的胶体金溶液,抗原溶液与胶体金溶液的体积比为1-10:100,同时加入稳定剂以防止头孢菌素类抗原与胶体金颗粒聚合沉淀,即得胶体金-头孢菌素类抗原结合物;所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇;
4)胶体金标记的头孢菌素类抗原的纯化:将步骤3)中制备的胶体金-头孢菌素类抗原结合物经1500r/min离心20min;收集沉淀溶于稳定剂中,使其浓度达到5-30%;然后加至Sephacryl S-400层析柱上进行纯化,将纯化的胶体金标记的头孢菌素类抗原溶液过滤除菌,4℃保存;所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液;
5)试纸条的包被:将步骤4)中制备的胶体金标记的头孢菌素类抗原溶液喷线于试纸条上,干燥后即得用于特异性头孢菌素类过敏原IgE筛查的试纸条成品。
7.根据权利要求6所述的方法,其特征在于,步骤4)中加样量为Sephacryl S-400层析柱体积的1/10,以稳定剂作为洗脱液,流速为5-10ml/h;所述稳定剂为1%BSA和0.1%分子量20KD的聚乙二醇溶液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410232547.4A CN103995116B (zh) | 2014-05-28 | 2014-05-28 | 用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410232547.4A CN103995116B (zh) | 2014-05-28 | 2014-05-28 | 用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103995116A true CN103995116A (zh) | 2014-08-20 |
CN103995116B CN103995116B (zh) | 2016-01-13 |
Family
ID=51309337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410232547.4A Active CN103995116B (zh) | 2014-05-28 | 2014-05-28 | 用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103995116B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114167050A (zh) * | 2021-12-09 | 2022-03-11 | 牟奕 | C型青霉素类与头孢菌素类抗生素抗体检测的固相矩阵及其制备方法 |
CN114200126A (zh) * | 2021-12-09 | 2022-03-18 | 牟奕 | N型青霉素类与头孢菌素类抗生素抗体检测的固相矩阵及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002056017A1 (en) * | 2000-10-13 | 2002-07-18 | Dexall Biomedical Labs, Inc. | Lateral flow assay for detection of antibodies in human serum |
US20060166374A1 (en) * | 2005-01-21 | 2006-07-27 | Hubscher Thomas T | Method for the visual detection of specific antibodies by the use of lateral flow assays |
CN101059513A (zh) * | 2007-05-31 | 2007-10-24 | 杭州迪恩科技有限公司 | 检测食品中药物残留的方法及其设备 |
CN101266246A (zh) * | 2008-04-30 | 2008-09-17 | 天津中新科炬生物制药有限公司 | 人类免疫缺陷病毒(hiv)抗体和抗原联合快速检测试剂盒 |
CN101387643A (zh) * | 2008-10-20 | 2009-03-18 | 杭州浙大生物基因工程有限公司 | 多通道过敏原快速检测试剂盒及其制备方法 |
CN102636650A (zh) * | 2012-03-23 | 2012-08-15 | 沃克(天津)生物科技有限公司 | 牛奶过敏原检测板及其制备方法 |
-
2014
- 2014-05-28 CN CN201410232547.4A patent/CN103995116B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002056017A1 (en) * | 2000-10-13 | 2002-07-18 | Dexall Biomedical Labs, Inc. | Lateral flow assay for detection of antibodies in human serum |
US6528325B1 (en) * | 2000-10-13 | 2003-03-04 | Dexall Biomedical Labs, Inc. | Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays |
US20060166374A1 (en) * | 2005-01-21 | 2006-07-27 | Hubscher Thomas T | Method for the visual detection of specific antibodies by the use of lateral flow assays |
CN101059513A (zh) * | 2007-05-31 | 2007-10-24 | 杭州迪恩科技有限公司 | 检测食品中药物残留的方法及其设备 |
CN101266246A (zh) * | 2008-04-30 | 2008-09-17 | 天津中新科炬生物制药有限公司 | 人类免疫缺陷病毒(hiv)抗体和抗原联合快速检测试剂盒 |
CN101387643A (zh) * | 2008-10-20 | 2009-03-18 | 杭州浙大生物基因工程有限公司 | 多通道过敏原快速检测试剂盒及其制备方法 |
CN102636650A (zh) * | 2012-03-23 | 2012-08-15 | 沃克(天津)生物科技有限公司 | 牛奶过敏原检测板及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114167050A (zh) * | 2021-12-09 | 2022-03-11 | 牟奕 | C型青霉素类与头孢菌素类抗生素抗体检测的固相矩阵及其制备方法 |
CN114200126A (zh) * | 2021-12-09 | 2022-03-18 | 牟奕 | N型青霉素类与头孢菌素类抗生素抗体检测的固相矩阵及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103995116B (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103995112B (zh) | 用于特异性动物毛皮屑过敏原IgE筛查的试纸条及其制备方法 | |
CN110133283A (zh) | Pct和il-6联合检测试剂盒及其制备方法 | |
WO2016111619A1 (en) | Methods for detecting a marker for active tuberculosis | |
CN103983789B (zh) | 用于特异性尘螨类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995116B (zh) | 用于特异性头孢菌素类抗生素过敏原IgE筛查的试纸条及其制备方法 | |
CN103995113B (zh) | 用于特异性破伤风抗毒素过敏原IgE筛查的试纸条及其制备方法 | |
CN103995135B (zh) | 用于特异性蘑菇类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995131B (zh) | 用于特异性杂草类花粉过敏原IgE筛查的试纸条及其制备方法 | |
CN103995132B (zh) | 用于特异性谷类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995133B (zh) | 用于特异性蛋清过敏原IgE筛查的试纸条及其制备方法 | |
CN103995115B (zh) | 用于特异性害虫类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995105B (zh) | 用于特异性胰岛素过敏原IgE筛查的试纸条及其制备方法 | |
CN103995106B (zh) | 用于特异性香料类过敏原IgE筛查的试纸条及其制备方法 | |
CN103983790B (zh) | 用于特异性蚕丝类过敏原IgE筛查的试纸条及其制备方法 | |
CN103983788B (zh) | 用于特异性奶类过敏原IgE筛查的试纸条及其制备方法 | |
CN202837303U (zh) | Ngal荧光免疫层析定量检测试纸条 | |
JP2007525643A5 (zh) | ||
CN103995114B (zh) | 用于特异性坚果类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995117B (zh) | 用于特异性真菌类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995134B (zh) | 用于特异性棉花类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995109B (zh) | 用于特异性水果类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995118B (zh) | 用于肉类过敏原IgE筛查的试纸条及其制备方法 | |
CN103995111B (zh) | 用于蔬菜类食物过敏原IgE筛查的试纸条及其制备方法 | |
CN103995110B (zh) | 用于特异性水产类过敏原IgE筛查的试纸条及其制备方法 | |
CN114563570B (zh) | 一种信号放大技术在pgp9.5检测试剂盒中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |